U.S. Markets closed

Free Stock Performance Review on Array BioPharma and Three More Biotech Industry

Stock Research Monitor: ITCI, ARGS, and AUPH

LONDON, UK / ACCESSWIRE / May 16, 2018 / If you want a free Stock Review on ARRY sign up now at www.wallstequities.com/registration. On Tuesday, the NASDAQ Composite ended the day at 7,351.63, down 0.81%; the Dow Jones Industrial Average edged 0.78% lower, to finish at 24,706.41; and the S&P 500 closed at 2,711.45, marginally slipping 0.68%. Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Intra-Cellular Therapies Inc. (NASDAQ: ITCI), Argos Therapeutics Inc. (NASDAQ: ARGS), Array BioPharma Inc. (NASDAQ: ARRY), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Intra-Cellular Therapies

New York headquartered Intra-Cellular Therapies Inc.'s stock finished Tuesday's session 0.77% higher at $20.93 with a total trading volume of 244,492 shares. The stock has gained 18.05% over the past three months and 87.54% in the previous twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 1.20% and 20.75%, respectively. Moreover, shares of Intra-Cellular Therapies, which engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases, have a Relative Strength Index (RSI) of 57.90. Get the full research report on ITCI for free by clicking below at:

www.wallstequities.com/registration/?symbol=ITCI

Argos Therapeutics

Shares in Durham, North Carolina-based Argos Therapeutics Inc. rose 2.68%, ending yesterday's session at $0.19 with a total trading volume of 30,752 shares. The Company's shares are trading below their 50-day moving average by 75.79%. Moreover, shares of Argos Therapeutics, which focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America, have an RSI of 27.31. Gain free access to the research report on ARGS at:

www.wallstequities.com/registration/?symbol=ARGS

Array BioPharma

On Tuesday, Boulder, Colorado headquartered Array BioPharma Inc.'s stock saw a decline of 2.60%, to close the day at $15.36. A total volume of 2.09 million shares was traded. The Company's shares have advanced 86.86% over the last twelve months. The stock is trading above its 200-day moving average by 19.06%. Additionally, shares of Array BioPharma, which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and Asia/Pacific, have an RSI of 56.34. Register for your free report coverage on ARRY at:

www.wallstequities.com/registration/?symbol=ARRY

Aurinia Pharmaceuticals

Shares in Victoria, Canada headquartered Aurinia Pharmaceuticals Inc. ended the day 0.80% higher at $6.28. A total volume of 1.56 million shares was traded, which was above their three months average volume of 613.88 thousand shares. The stock has gained 15.65% in the last month and 19.62% in the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 16.95% and 11.93%, respectively. Furthermore, shares of Aurinia Pharma, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally, have an RSI of 77.65. Get the free research report on AUPH at:

www.wallstequities.com/registration/?symbol=AUPH

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

  • Mega Millions $1.6 Billion Jackpot Also Comes With a Mega Millions Tax Bill
    Finance
    Fortune

    Mega Millions $1.6 Billion Jackpot Also Comes With a Mega Millions Tax Bill

    With a jackpot of $1.6 billion, tonight’s Mega Millions lottery drawing is the biggest in history. The Mega Millions drawing will be held Tuesday night at 11 p.m. ET—and the odds are categorically against you. The Mega Millions tax bite, though, is pretty solid.

  • Companies Say They're Ready to Move Supply Chains From China
    News
    Bloomberg

    Companies Say They're Ready to Move Supply Chains From China

    A common theme is that they are ready to relocate supply chains if the cost of importing Chinese goods becomes prohibitive. "If there was a broad-based tariff on apparel, I think you could see a bit more of an acceleration of the migration out of China into other regions for apparel sourcing," Mitch Butier, chief executive officer of the California label producer, said during an Oct. 23 earnings call. A number of them have already moved out of China," Jean-Jacques Ruest, CEO of the Canadian railway company said during an Oct. 23 earnings call.

  • 4 Things Aurora Cannabis Did Right Before Its NYSE Debut
    Business
    Motley Fool

    4 Things Aurora Cannabis Did Right Before Its NYSE Debut

    Aurora Cannabis (NASDAQOTH: ACBFF) (TSX: ACB) has sought to make it even easier for U.S. investors to buy its shares by arranging to have its shares listed on the New York Stock Exchange. Beginning tomorrow, Oct. 23, Aurora will join the elite group of cannabis companies whose shares trade on major U.S. exchanges. Getting ready for the increased exposure that a NYSE listing brings takes time and effort, and Aurora Cannabis hasn't wasted any time.

  • The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says
    Business
    Business Insider

    The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says

    The stock market may have bounced back from its sharp sell-off at the beginning of October, but Morgan Stanley says the selling will pick back up soon. The firm expects the S&P 500 to slide back below the 200-day moving average, a key technical level. Tread carefully in tech and consumer discretionary, Morgan Stanley warns.

  • Why Investors Are Paying a Premium for These 3 Biotech Stocks
    Business
    Motley Fool

    Why Investors Are Paying a Premium for These 3 Biotech Stocks

    Amarin stock exploded in September because it looks like Vascepa will become the next go-to drug for this enormous population. During the 8,179-patient Reduce-It trial, patients given Vascepa in addition to their normal statin treatments were 25% less likely to suffer a major cardiovascular event such as a heart attack. Over the past year, Amarin Corporation actually lost $92 million because sales of Vascepa just haven't kept pace with operating expenses.

  • Suze Orman missed the point of retirement, and that’s why she went back to work
    News
    MarketWatch

    Suze Orman missed the point of retirement, and that’s why she went back to work

    Suze Orman did a smackdown of the FIRE (Financial Independence/Retire Early) movement on Paula Pant’s podcast. Coach Carson posted a balanced, informative response, appreciating Suze’s admonition to be sure you have enough for a risk-free retirement. Suze enumerated a string “what can go wrong” scenarios as evidence that early retirement (on less than $10 million) leaves you vulnerable when life hands you lemons — a whole tree of lemons.

  • 5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade
    Business
    Motley Fool

    5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade

    October has been a wake-up call for investors that the stock market won't go up in a straight line, even if we'd like it to. Sure, Bank of America (NYSE: BAC) has seen its stock catapult higher from its Great Recession lows, but its forward P/E of 9.8 would represent a more-than-decade low for the stock.

  • MARKETS: Here's why stocks are selling off right now and what a bottom would look like
    Business
    Yahoo Finance Video

    MARKETS: Here's why stocks are selling off right now and what a bottom would look like

    Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Seana Smith to discuss the latest market moves.

  • Finance
    InvestorPlace

    Advanced Micro Devices Stock Is Finally Ready for a Strong Comeback

    During that stretch, I was bullish on AMD stock from $20 all the way to $30. Does that mean it’s time to buy back into AMD stock? Advanced Micro Devices stock has dropped a bunch over the past several weeks because Intel (NASDAQ:INTC) is reportedly gaining traction when it comes to volume production of next-gen chips.

  • News
    CNBC

    Here's how much money you should have saved by 50

    Fidelity, the nation's largest retirement-plan provider, recommends having the equivalent of six times your annual salary saved. To get to that number, Fidelity recommends saving 15 percent of your annual income. Make sure to invest these funds instead of leaving them in a traditional low-interest savings account.

  • Banks vs. Big Tech: 4 to Buy, 4 to Sell
    Finance
    InvestorPlace

    Banks vs. Big Tech: 4 to Buy, 4 to Sell

    Investors on Wall Street continue to contend with a choppy and uncertain trading environment, even among popular sectors like tech stocks. A growing chorus on Wall Street is sounding the alarm, with analysts at Morgan Stanley warning that the large-cap stocks in the S&P 500 are the only holdout from a “rolling bear market’ that has already savaged pretty much every other asset class, including small-cap stocks, high-yield bonds, and emerging market assets. The fact that the S&P 500 is once again below its 200-day moving average supports this thesis, weighed down by bank stocks.

  • Tesla Stock Is Up 10.2%: What’s Helping It Defy Gravity?
    Finance
    Market Realist

    Tesla Stock Is Up 10.2%: What’s Helping It Defy Gravity?

    Tesla (TSLA) stock appears to be defying gravity today and is rallying despite the broader market sell-off. Today at 1:08 PM EDT, Tesla stock was up 10.2% from the previous session’s closing price. Earlier today, Citron Research—one of the Tesla bears—surprised the market by turning positive on TSLA for the first time.

  • Why Tesla Pushed Up Q3 Earnings Report
    Business
    Bloomberg

    Why Tesla Pushed Up Q3 Earnings Report

    Oct.23 -- Tesla Inc.’s pulled forward its third-quarter earnings release to post-market on Oct. 24. Bloomberg Businessweek's Max Chafkin and Pierre Ferragu, analyst at New Street research, discuss the factors behind the decision and outlook for the electric automaker on "Bloomberg Technology,"

  • Trump’s Tax Push to Help Middle Class Could Help Top Earners Too
    Politics
    Bloomberg

    Trump’s Tax Push to Help Middle Class Could Help Top Earners Too

    It’s still unclear how Trump will propose to reduce the tax burden on middle-class Americans, but one of the most straightforward ways would be to lower rates by 10 percent for single filers making up to $82,500. U.S. income tax rates are graduated and income dollars get taxed in chunks as they move up through the brackets -- which means wealthy Americans would also get to apply the reduced rate on their first dollars of income. “A millionaire gets the same size tax cut,” said Kyle Pomerleau, an economist at the conservative Tax Foundation.

  • Caterpillar's Q3 beat expectations, shares tumble
    Finance
    Yahoo Finance

    Caterpillar's Q3 beat expectations, shares tumble

    A Caterpillar Inc. equipment is on display for sale at a retail site in San Diego, California, U.S., March 3, 2017. Global construction equipment giant Caterpillar (CAT) announced quarterly results that were a bit better than expected. Caterpillar’s construction industries business segment sales grew 16% to $5.7 billion.

  • Finance
    CNBC

    The fear gauge and strong earnings tell Jim Cramer this bottom in the stock market may be real

    The Cboe Volatility Index and strong earnings reports from key companies helped stocks recover intraday on Tuesday, CNBC's Jim Cramer says. The Cboe Volatility Index , also known as the stock market's fear gauge or the VIX, flashed a signal that could mean the market bottomed during Tuesday's turbulent trading session , CNBC's Jim Cramer said. Last week, the "Mad Money" host called on technician Mark Sebastian, who specializes in volatility, to get a read on the VIX , which measures expectations of near-term volatility by tracking S&P 500 option prices.

  • Why Nektar Therapeutics Crashed 17.2% Today
    Business
    Motley Fool

    Why Nektar Therapeutics Crashed 17.2% Today

    After delivering a disappointing update on NKTR-214 in cancer patients this summer, Nektar Therapeutics' (NASDAQ: NKTR) shares have been struggling. The company didn't report any news today, so a negative report issued by Plainview LLC this month may be to blamed for its 17.2% tumble today. In February, Bristol-Myers Squibb (NYSE: BMY) inked a blockbuster deal to license rights to NKTR-214 following positive data last year for NKTR-214's use alongside Bristol-Myers' Opdivo.

  • 2 More Marijuana Stocks Are Moving to the NYSE
    Business
    Motley Fool

    2 More Marijuana Stocks Are Moving to the NYSE

    This year, we've witnessed GW Pharmaceuticals gain approval in the U.S. for the first cannabis-derived drug, and we watched as Vermont legalized recreational marijuana use entirely through the legislative process. This began with Cronos Group at the end of February, when it chose to list its shares on the Nasdaq. It was followed just a few months later by Canopy Growth Corp., which became the first marijuana stock to list on the NYSE.

  • Why These 3 Top Marijuana Stocks Slumped Today
    Business
    Motley Fool

    Why These 3 Top Marijuana Stocks Slumped Today

    With earnings season hitting a crescendo this week, investors are looking closely at the specific prospects for certain corners of the market, and that's contributing to disparities among the various major benchmarks followed most often by investors. Amid the crosscurrents, marijuana stocks took particularly hard hits, and New Age Beverages (NASDAQ: NBEV), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) were among the worst performers on the day. All three of these stocks have given back some of their gains following the long-awaited legalization of recreational cannabis in the Canadian market last week. In the month leading up to the Oct. 17 start date for legal cannabis sales, New Age Beverages tripled in value, while Tilray had more than doubled since the end of August, and Canopy Growth had seen more modest gains of between 10% and 20%.

  • S&P 500 closes down for fifth day as stocks retreat in wake of China selloff
    News
    MarketWatch

    S&P 500 closes down for fifth day as stocks retreat in wake of China selloff

    U.S. stocks bounced off intraday lows and major indexes trimmed early losses Tuesday, but the S&P 500 still finished lower for a fifth session as a big drop in the Chinese market revived fresh questions about the global economy. The Dow Jones Industrial Average (DJIA) fell 125.98, or 0.5%, to 25,191.43 after being down more than 500 points earlier. (DJIA)On Monday, Dow industrials and the S&P 500 closed lower while the Nasdaq bucked the trend to edge higher.

  • Finance
    CNBC

    Here's the tax bite on $1.6 billion Mega Millions and $620 million Powerball jackpots

    Strategies can be employed to reduce the amount of your win that is taxed, although they are best explored with the help of an experienced tax advisor. While it's anyone's guess who will end up winning the Mega Millions and Powerball jackpots, there's at least one guaranteed recipient of a chunk of the loot — the IRS. With the Mega Millions jackpot at $1.6 billion and Powerball's top prize at $620 million, that tax bill will be hefty even if the winner employs strategies to reduce their taxable income.

  • The $1.6B Lottery Jackpot Is Still Up for Grabs — but the Tax Bill for the Winner Will Be Massive
    Finance
    GoBankingRates

    The $1.6B Lottery Jackpot Is Still Up for Grabs — but the Tax Bill for the Winner Will Be Massive

    Whoever wins the Mega Millions lottery could face over 40 percent in taxes. Lines are growing at convenience stores and gas stations as the Mega Millions lottery grows to its biggest prize ever. The cash option is $904 million, which gives you a lot of options of how to spend it until you take taxes into consideration.

  • Weed stocks are tanking as Aurora Cannabis debuts on the New York Stock Exchange (TLRY, CRON, CGC)
    Business
    Business Insider

    Weed stocks are tanking as Aurora Cannabis debuts on the New York Stock Exchange (TLRY, CRON, CGC)

    Aurora Cannabis made its trading debut on the New York Stock Exchange. Weed stocks are getting slammed across the board, trading down between 7% and 14% before paring their losses. Weed stocks were under pressure Tuesday morning as one of the largest cannabis producers, Aurora Cannabis, debuted for trading on the New York Stock Exchange.

  • Watch out for ‘dead cat bounce’ in stocks because there’s more pain ahead: Morgan Stanley’s Wilson
    News
    MarketWatch

    Watch out for ‘dead cat bounce’ in stocks because there’s more pain ahead: Morgan Stanley’s Wilson

    October is living up to its infamous reputation as a volatile month for stocks with major indexes down sharply and there is likely more pain ahead for investors, according to one prominent Wall Street analyst. The recent rebound “was a dead cat bounce,” said Michael Wilson, an equity strategist at Morgan Stanley, in a report. After eking out gains last week, the S&P 500 (SPX) is trading below the 200 DMA of 2,768 thus far this week as stocks remain under pressure with third-quarter earnings cycle picking up pace.

  • Marijuana Stocks Plummet to Record Low: What's Next?
    Business
    Zacks

    Marijuana Stocks Plummet to Record Low: What's Next?

    Over the last few days, share prices of major marijuana stocks have plummeted to their worst in the trailing eight months. This free fall commenced following the legalization of marijuana for recreational use in Canada on Oct 17.Legalization Considered